Clinical News

Clinical Status

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">Aurexis: Phase II completed enrollment</h1><div class="byline">WIR Staff</div><div class="date"></div></div></div></div>

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

INHX completed enrollment of 60 patients in a double-blind, placebo-controlled Phase II trial. ......

Infectious

Ophthalmic

Aurexis: Phase II completed enrollment

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery: Disruptive Innovation

Distillery

Hot Topics

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

Bio€quity Europe

BioCentury Grand Rounds 2024

BioCentury Grand Rounds

The BioCentury-BayHelix China Healthcare Summit

BioCentury-BayHelix China Healthcare Summit

The BioCentury Show

Webinars - Upcoming & On-Demand

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Request a Trial

Request a Subscription

Advertising - Sponsorship Inquiry

Media Kit

Request BioCentury's BCIQ Brochure

Customer Resource Center

Career Opportunities

Contact

Home